Biotech backer Forbion raises $120M toward a new VC fund

The Netherlands' Forbion Capital Partners has wrapped up the first close in a planned third fund, raking in $120 million with plans to stake a new generation of biotechs. Forbion expects to raise as much as $250 million for its new fund, enough to support 12 to 15 investments in therapeutics, devices and diagnostics. Among the group's recent exits are Santaris Pharma, sold to Roche ($RHHBY) in a $450 million deal; bluebird bio ($BLUE), which pulled off a $116 million IPO last year; and BioVex, which Amgen ($AMGN) acquired for up to $1 billion. More (PDF)

Suggested Articles

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.

Grid Therapeutics is planning to start trials of its lead cancer immunotherapy GT103 next year after raising $5 million in second-round financing.

The IPO comes as the Flagship startup prepares to test its lead inflammatory disease and anticancer microbial strains in humans.